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Abstract  
SHORT syndrome has historically been defined by its acronym: short stature (S), 
hyperextensibility of joints and/or inguinal hernia (H), ocular depression (O), Rieger 
abnormality (R) and teething delay (T). More recently several research groups have identified 
PIK3R1 mutations as responsible for SHORT syndrome. Knowledge of the molecular 
etiology of SHORT syndrome has permitted a reassessment of the clinical phenotype. The 
detailed phenotypes of 32 individuals with SHORT syndrome and PIK3R1 mutation, 
including eight newly ascertained individuals, were studied to fully define the syndrome and 
the indications for PIK3R1 testing. The major features described in the SHORT acronym were 
not universally seen and only half (52%) had 4 or more of the classic features.  The 
commonly observed clinical features of SHORT syndrome seen in the cohort included IUGR 
< 10th percentile, postnatal growth restriction, lipoatrophy and the characteristic facial gestalt. 
Anterior chamber defects and insulin resistance or diabetes were also observed but were not 
as prevalent.  The less specific, or minor features of SHORT syndrome include teething delay, 
thin wrinkled skin, speech delay, sensorineural deafness, hyperextensibility of joints and 
inguinal hernia. Given the high risk of diabetes mellitus, regular monitoring of glucose 
metabolism is warranted. An echocardiogram, ophthalmological and hearing assessments are 
also recommended.  
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Introduction 
SHORT syndrome (MIM 269880) has been clinically defined by its acronym: Short 
stature, Hyperextensibility of joints or inguinal Hernia or both, Ocular depression, Rieger 
abnormality and Teething delay 1. Additional clinical features include intrauterine growth 
restriction (IUGR), facial dysmorphism (triangular face, prominent forehead, deep-set eyes, 
hypoplastic or thin alae nasi, mild midface hypoplasia, small chin, large low-set ears, thin 
vermillion, border and downturned mouth) with wrinkled and thin skin that accentuates a 
progeroid appearance. The identification of the gene responsible for SHORT syndrome has 
highlighted that lipodystrophy and insulin resistance are predominant signs of the condition 2-4 
Some authors have reported similar features without the label of SHORT syndrome but in 
retrospect these individuals had the same condition5-6. The differential diagnoses for SHORT 
syndrome include several recognizable syndromes with growth deficiency and similar facial 
appearance such as Russel Silver (MIM180860) or Floating Harbor syndrome (MIM136140). 
In addition mutations that involve PITX2 (MIM601542), FOXC1 (MIM601090) or BMP4 
(MIM112262) can been seen in patients with anterior chamber defects of the eye.  
An autosomal dominant inheritance has been confirmed by the identification of 
heterozygous mutations in PIK3R1 (MIM171833) as the cause of SHORT syndrome 2-4. A 
total of seven different mutations were reported in 24 individuals with SHORT syndrome, and 
highlighted a recurrent substitution (p.Arg649Trp)7-8. PIK3R1 codes for the regulatory 
subunits of the phosphatidyl inositol-3 kinase of classe IA (PI3K) and is involved in 
activation of the AKT/mTOR pathway to ensure proper growth and cell proliferation 9-10. 
Mutations are located in a region that encodes the src-homology 2 (SH2) domains of PIK3R1 
protein, domains that are present in the three known isoforms of the protein (p85α, p55α and 
p50α; Supplemental figure 1). The SH2 domains play a role in the regulatory activity of the 
PI3K and i-SH2 domain is known to perform a link with the ABD domain of the catalytic 
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subunit of PI3K (p110α) allowing the formation of a dimer 9-10. Therefore all mutations 
presented to date are within i-SH2 and c-SH2 domains and probably impact the regulatory 
activity of PIK3R1.  PIK3R1 mutations in SHORT syndrome appear to disrupt the insulin 
signaling pathway and thereby predispose to insulin resistance and diabetes. Downstream 
effects appear to be mediated by lower levels of phosphorylation of proteins in the AKT and 
mTOR signalling pathway 2-4.   
To characterize the salient clinical features of SHORT syndrome, we present 8 
unpublished patients and the previously reported patients with confirmed PIK3R1 mutations.  
We highlight the clinical features that should prompt consideration of SHORT syndrome as a 
potential diagnosis and that can serve as indications for further molecular testing of PIK3R1.  
We also suggest recommendations for medical management  
 
Patients and Methods 
Detailed phenotypes of 8 newly ascertained individuals and the 24 previously reported 
SHORT syndrome patients with causal PIK3R1 mutation 2-4;7-8 were collected, with particular 
emphasis on the features of the acronym, facial dysmorphism and lipodystrophy (Table 1). 
Clinical and biological metabolic data were also collected (Supplemental tables 1 and 2).  
 
Results  
Thirty-two SHORT individuals with PIK3R1 mutations from 24 families were 
included in the evaluation (Table 1; Figure 1). There were 18 males and 14 females. Mean age 
at last follow-up was 21 years of age. The eight newly ascertained patients included 4 females 
and 4 males. Two cases presented with a family history of SHORT syndrome. Six patients of 
the newly identified patients had the recurrent substitution, p.Arg649Trp, and two patients 
(father and son) had a novel mutation that was the most distal of the PIK3R1 mutations. 
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The features of the SHORT syndrome acronym varied in their frequency: 11/21 cases 
(52%) presented at least 4 of 5 signs of this acronym. Short stature was described for 25/31 
cases and 22/28 cases presented with height below -3SD. Deep-set eyes (ocular depression; 
27/27 cases) and teething delay (20/20 cases) were constant but hyperextensibility of joints or 
inguinal hernia (10/29 cases) and Rieger abnormality (13/30 cases) appeared less commonly. 
In cases without Rieger abnormality, some patients presented with other abnormalities of the 
anterior chamber of eye (5/16 cases). In addition, several cases presented with hyperopia, 
astigmatism or myopia (12/24 cases). The facial gestalt was remarkably consistent (32/32 
cases) (Figure 1; Table 1), including progeroid appearance (27/31 cases), triangular face 
(31/31 cases), a prominent forehead (31/32 cases), deep set eyes (27/27 cases), thin and 
hypoplastic alae nasi (29/30 cases), mild midface hypoplasia (25/30 cases), small chin (28/32 
cases), large low-set ears (27/30 cases), thin lip and downturned mouth (29/31 cases). In 
19/26 cases, thin, wrinkled skin and readily visible veins were also described. The late IUGR 
was also frequent (22/26 cases), leading to low birth weight that was frequently less than the 
third percentile (19/25 cases).  
Clinical lipoatrophy, generalized or partial (8/29 cases), was present in most (26/29 
cases) with body mass index (BMI) commonly less than the third centile (22/29 cases). 
Patients frequently presented with insulin resistance (13/17 cases), with a highly variable age 
at diagnosis ranging from 7 to 49 years. After 15 years of age, 9/14 cases had insulin resistant 
diabetes, with high insulin requirements (>1.5 U/Kg/d). In patients without diabetes, insulin 
resistance was frequent (4/8 cases), as assessed by increased insulinemia. Gynecological 
investigations revealed polycystic ovary syndrome in all tested postpubertal women (5/5 cases 
among the 9 postpubertal women).  
Most patients had normal educational achievements (23/26 cases) but there were three 
cases reported as having cognitive delay: one of whom had a history of severe prematurity 
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and cerebral hemorrhage (P1 7; P9 2). Other than this patient, intellectual disability was 
reported as mild in the two others, but this data should be interpreted with caution in the 
absence of detailed neurocognitive testing. Approximately half of the patients presented with 
a history of mild speech delay (14/27 cases).  
The patients presented with other features: three patients had cardiac abnormalities 
(2/3 pulmonary stenosis and 1/3 ventricular septal defect) 3; 7; 8. Five patients also presented 
with sensorineural deafness (new patients 1, 2 and 7; 3) (Supplemental Table 1). 
The 32 cases from 24 families presented with 9 different mutations, highlighting a 
mutational hotspot in 16 families and 23 cases (c.1945C>T; p.Arg649Trp). All mutations 
were in the two SH2 domains (Supplemental Figure 1). Otherwise, there was no obvious 
genotype-phenotype correlation within this group.  However, it was noted that the father and 
son with the substitution at the most distal position of the protein p.Gly665Ser had a less 
striking facial appearance than others in the cohort (Figure 1K, L) and the proband was 
sequenced as part of a study to identify novel genes in anterior chamber defects and a 
diagnosis of SHORT syndrome was not initially considered. 
 
Discussion 
This study presented a meta-analysis of the available clinical data in SHORT 
syndrome, in the context of the PIK3R1 causative gene discovery. The results showed that the 
historically defining features of the acronym were seen in less than half of patients (ie. 
hyperextensibilty of joints/inguinal hernia and Rieger anomaly), and that only 52% of patients 
presented with at least 4 of 5 signs of the SHORT acronym (Table 1). The reassessment also 
showed that three cardinal clinical features of the condition are absent from the acronym, 
including subcutaneous lipoatrophy, insulin resistance and the facial gestalt (not only ocular 
depression). The lipoatrophy is often generalized, with a BMI frequently less than the third 
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percentile. Insulin resistance was seen in a majority of those investigated (13/17) and it 
showed a wide range in its age of onset with 7 years being the earliest.  Facial dysmorphism 
appears more pronounced with age, with a progeroid aspect accentuated by a lack of facial fat 
and by thin and wrinkled skin (Figure 1): a triangular appearance to the face, broad forehead, 
deep-set eyes, and a nose with thin nasal alae, and a low-hanging columella, thin lip and 
down-turned mouth. The chin can be dimpled and ears are prominent and low-set.  
We also particularly focused on the natural history of the syndrome to establish 
recommendations for medical follow-up in individuals with SHORT syndrome (Table 3). In 
infancy, a cardiac assessment would be warranted given the potential of heart malformation 
(particularly pulmonary stenosis), as well as hearing loss screening because of possible 
sensorineural hearing loss in first year of life. An ophthalmological assessment would also be 
important given the risk of Rieger abnormality and possible glaucoma. In childhood, 
assessment of height and developmental milestones, in particular language development 
should be monitored. Because of the PIK3R1 implication in insulin signaling and the frequent 
insulin resistance seen in individuals with SHORT syndrome, the occurrence of diabetes 
mellitus should be screened for by annual HbA1c, fasting glucose and an insulin level. When 
these investigations appear normal, an oral glucose tolerance test (OGTT) with measurement 
of glucose and insulin, to look for glucose intolerance and insulin resistance, should be 
considered in order to adapt dietary recommendations and treatment. SHORT patients present 
also with short stature with an adult height in males ranging between 153,7 and 167 cm and in 
females between 141 and 160 cm 2-4. Indeed, it is known that PI3K/Akt pathway does not 
appear only the signaling pathway of insulin receptor but also of other receptors like insulin-
like growth factor 1 (IGF1) receptor 14, explaining short stature, IUGR and deafness. Because 
GH treatment associated with a risk of decreased insulin sensitivity could aggravate the pre-
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existing insulin resistance and accelerate the onset of diabetes mellitus, its benefits/risk should 
be evaluated with caution. 
In conclusion, the identification of mutations in PIK3R1 as responsible for SHORT 
syndrome has permitted a re-evaluation of the SHORT syndrome phenotype.  These results 
highlight the importance of the IUGR, lipoatrophy, facial gestalt and insulin 
resistance/diabetes as cardinal features not captured in the acronym. While we do not 
advocate a change in the syndrome name, in part to avoid confusion in the literature, we stress 
the importance of fully characterizing the clinical aspects of SHORT syndrome so that the 
clinician can recognize and initiate molecular testing. Given knowledge of the pathway, 
SHORT syndrome can be grouped with other syndromes due to aberrant insulin signaling (for 
example Donohue syndrome).  Other mutations affecting this same pathway may lead to the 
delineation of additional phenotypes with overlapping clinical features to SHORT 
syndrome.15  
 
 
A
cc
ep
te
d 
A
rti
cl
e
References 
 
1. Gorlin, R. J. A selected miscellany.Birth Defects Orig. Art. Ser. 1975; 11(2): 39-50 
2. Thauvin-Robinet C.*, Auclair M.*, Duplomb L.*; Caron-Debarle M., Avila M., St-
Onge J., Le Merrer M., Le Luyer B., Héron D., Mathieu-Dramard M., Bitoun P., Petit 
J-M., Odent S., Amiel J., Picot D., Carmignac V., Thevenon J., Callier P., Laville M., 
Reznik Y., Fagour C., Nunes M-L., Capeau J., Lascols O., Huet F., Faivre L., 
Vigouroux C., and Rivière J-B. PIK3R1 Mutations Cause Syndromic Insulin 
Resistance with Lipoatrophy. Am J Med Genet. 2013; 93(11): 141-149. doi: 
10.1016/j.ajhg.2013.05.019. 
3. Dyment D.A., Smith A.C., Alcantara D., Schwartzentruber J, Basel-Vanagaite L., 
Curry, C.J., Temple I.K., Reardon W., Mansour S., Haq M.R., Gilbert R., Lehmann 
O.J., Vanstone M.R., Beaulieu C.L., FORGE Canada Consortium, Majewski J., 
Bulman D.E., O’Driscoll M., Boycott K.M., and Innes A.M. Mutations in PIK3R1 
Cause SHORT Syndrome. Am J Med Genet. 2013 ; 93(11) : 158-166. doi: 
10.1016/j.ajhg.2013.06.005.  
4. Chudasama K.K., Winnay J., Johanson S., Claudi T., König R., Haldorsen I., 
Johansson B., Woo J.R., Aarskog D., Sagen J.V., Kahn C.R., Molven A., and Njolstad 
P.R. SHORT Syndrome with Partial Lipodystrophy due to Impaired 
Phosphatidylinositol 3 kinase Signaling. Am J Med Genet. 2013 ; 93(11) : 150-157. 
doi: 10.1016/j.ajhg.2013.05.023.  
5. Aarskog D., Ose L., Pande H., Eide N. Autosomal dominant partial lipodystrophy 
associated with Rieger anomaly, short stature, and insulinopenic diabetes. Am. J. Med. 
Genet. 1983; 15: 29-38.  
6. Bankier A., Keith C. G., Temple I. K. Absent iris stroma, narrow body build and small 
facial bones: a new association or variant of SHORT syndrome? Clin. Dysmorph. 
1995; 4: 304-312 
7. Schroeder C., Riess A., Bonin M., Bauer P., Riess O., Döbler-Neumann M., Wieser S., 
Moog U., Tzschach A. PIK3R1 mutations in SHORT syndrome. Clin Genet; 2014; 
86(3):  292-4. doi: 10.1111/cge. 12263. 
8. Barcena C., Quesada V., De sandre-Giovannoli A., A Puente D., Fernandez-Toral J., 
Sigaudy S., Baban A., Lévy N., Velasco G., Lopez-Otin C. Exome sequencing 
identifies a novel mutation in PIK3R1 as the cause of SHORT syndrome. BMC. 2014; 
15:51. doi: 10.1186/1471-2350-15-51. 
9. Miled N., Yan Y., Hon W-C., Perisic O., Zvelebil M., Inbar Y., Schneidman-
DuhovnybD., Wolfson H. J., Backer J. M., Williams R. L. Mechanism of  Two 
Classes of Cancer Mutations in the Phosphoinositide 3-Kinase Catalytic Subunit. 
Science. 2007; 317: 239-242. Doi: 10.1126/science.1135394. 
10. Hofmann B., Jücker M. Activation of PI3K/Akt signaling by n-terminal SH2 domain 
mutants of the p85α regulatory subunit of PI3K is enhanced by deletion of its c-
terminal SH2 domain. Cellular Signalling.2012; 24: 1950-1954. doi: 
10.1016/j.cellsig.2012.06.009.  
11. Engelman J. A., Luo J., Cantley L. C. The evolution of phosphatidylinositol 3-kinase 
as regulators of growth and metabolism. Nature Genetics. 2006; 7: 606-619. doi: 
10.1038/nrg1879. 
12. Reardon W., Temple I. K. Nephrocalcinosis and disordered calcium metabolism in 
two children with SHORT syndrome. AM. J. Med. Genet. 2008; 146A: 1296-1298. 
doi: 10.1002/ajmg.a.32250. 
13. Amiel S.A., Sherwin R.S., Simonson D.C., Lauritano A.A., Tamborlane W.V. 
Impaired insulin action in puberty. A contributing factor to poor glycemic control in 
A
cc
ep
te
d 
A
rti
cl
e
adolescents with diabetes. N. Engl. J. Med. 1986 ; 315:215-219. doi: 
10.1056/NEJM198607243150402. 
14. Klammt J., Pfaffle R., Werner H., Kiess W. IGF signaling defects as cause of growth 
failure and IUGR. Trends in Endocrinology and Metabolism.2008; 19 (6): 197-205. 
doi: 10.1016/j.tem. 2008.03.003.  
15. Prontera P, Micale L, Verrotti A, Napolioni V, Stangoni G, Merla G. A New 
Homozygous IGF1R Variant Defines a Clinically Recognizable Incomplete Dominant 
form of SHORT Syndrome. Hum Mutat 2015 
 
 
 
A
cc
ep
te
d 
A
rti
cl
e
Legend
 
 
 
Figure 1
 
 
 
Figure 1
3; g-h: 
father o
patient p
 
 
 
 
 
 
 
 
 
 
 
 
 
 
s 
 
: Pictures 
patient 5; i
f patient 7 a
reviously r
of new case
-j: patient 6
lso showin
eported (m
s of SHOR
; k: patien
g mild faci
-o: P4 of D
T syndrom
t 7 with re
al phenotyp
yment et al
e (a-c: pati
lative mild 
e), and unp
. 2013) sho
ent 1; d-e: 
facial phen
ublished im
wing typica
patient 2; f
otype; l: p
ages of a 
l facial ges
: patient 
atient 8, 
SHORT 
talt. 
A
cc
ep
te
d 
A
rti
cl
e
 
 
Table 1 
 
 N= 32* 
IUGR 22/26 
IUGR ≤ 3rd percentile 19/25 
BMI ≤ 3rd percentile 22/29 
SHORT acronym signs  
S (short stature) (< -2SD) 25/31 
Height < -3SD 22/28 
Hyperextensibility of joints / inguinal Hernia  10/29 
O (ocular depression) 27/27 
R  (Rieger abnormality) 13/30 
T (Teething delay) 20/20 
Number of acronym signs ≥ 4/5  11/21 
Facial dysmorphism 32/32 
Triangular face 31/31 
Prominent forehead 31/32 
Hypoplastic or thin alea nasi 29/30 
Mild midface hypoplasia 25/30 
Small chin or micrognatia 28/32 
Large low-set ears 27/30 
Thin lip and downturned mouth 29/31 
Progeroid face 27/31 
Other signs  
Refractive errors 12/24 
Anterior chamber of eye abnormalities (without 
Rieger anomaly) 
5/16 
Lipoatrophy 26/29 
Thin, wrinkled skin and readily visible veins 19/26 
Absence of hypertriglyceridemia 18/18 
Insulin resistance 13/17
Diabetes (≥15 y) 9/14 
Ovarian cysts 5/5 
Intellectual deficiency 3/26** 
Speech delay 14/27 
* including 18 males and 14 females, as well as 8 new SHORT 
patients (4 females and 4 males) from France, Spain, China, Australia, 
USA and Canada and the 24 previously reported. 
** one of whom had a history of severe prematurity and cerebral 
hemorrhage (P1 7; P9 2). The intellectual disability reported as mild in 
the two others should be interpreted with caution in the absence of 
detailed neurocognitive testing.
 
 
Table 1: Features of SHORT patients 
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Table 2  
 
Clinical indications for PIK3R1 molecular testing  
Major features 
1 – IUGR < 10th per 
2 – Post natal growth retardation (height < -2SD)  
3 – Lipoatrophy with normal triglyceride assay 
4 – Anterior chamber abnormality (including Rieger abnormality) 
5 – Facial gestalt  
6 – Insulin resistance or diabetes  
Minor features 
1 – Teething delay 
2 – Thin wrinkled skin with readily visible veins 
3 – Speech delay 
4 – Hyperextensibility of joints 
5 – Inguinal hernia 
6 – Hyperopia 
 
 
 
 
 
 
Table 2:  Clinical indications for PIK3R1 molecular testing: Shows the major features that are 
commonly seen or are specific to the syndrome as well as the minor features that are less 
specific and/or less frequent in SHORT syndrome 
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Table 3 
 
At diagnosis Follow-up 
- Ophthalmological 
examination 
- Screening for hearing loss 
- Fasting glucose and insulin 
+/- OGTT (according to age) 
- Cardiac ultrasound 
- Abdominal ultrasound 
(occasional renal anomalies) 
- Lipid blood test 
(triglyceride) 
- Fasting glucose and insulin, 
HBA1c every year 
- OGTT every 5 years if no 
diabetes occurred  
- In women, gynecological 
ultrasound to search 
polycystic ovary 
- Screening for hearing loss 
- Monitor growth 
- Follow developmental 
milestones, in particular 
speech and langage 
 
 
Table 3: Recommendations of care monitoring at diagnosis and during follow-up 
Supplemental figure 1: schematic representation of the three isoforms encoded by PIK3R1, 
their functional domains and the mutations identified in patients. 
 
 
